Mercaptobenzothiazole

Mercaptobenzothiazole Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 232 adverse event reports referencing Mercaptobenzothiazole, including 2 reports in which the animal died — a 90.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Mercaptobenzothiazole. Reported administration routes include Topical, Oral, Unknown, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Mercaptobenzothiazole reports are Dog (129 reports), Human (80 reports), Cat (15 reports), with Dog accounting for the largest share. Within those species, Unknown (87), Crossbred Canine/dog (24), Dog (unknown) (18) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Mercaptobenzothiazole are Accidental exposure (109), Unclassifiable adverse event (97), No sign (61), Accidental drug intake by child (42). Of the 7 reports with a coded outcome, Outcome Unknown is the leading category at 71.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Mercaptobenzothiazole.